Clinical Efficacy of Netupitant and Palonosetron Hydrochloride Capsules Regimen in Preventing Chemotherapy-induced Nausea and Vomiting Associated with Cisplatin Chemotherapy for Lung Cancer
Objective:To explore the clinical efficacy of Netupitant and Palonosetron Hydrochloride Capsules regimen in preventing Cisplatin chemotherapy-induced nausea and vomiting(CINV)of lung cancer.Method:Clinical data of 80 patients with lung cancer who received Cisplatin chemotherapy in Quanzhou Hospital of Traditional Chinese Medicine from August 2021 to December 2023 were retrospectively collected,they were divided into two groups according to different treatment regiments,40 patients in the control group were given intravenous Dolasetron Mesylate Injection combined with Dexamethasone to prevent CINV;40 patients in the observation group were given oral Netupitant and Palonosetron Hydrochloride Capsules combined with Dexamethasone to prevent CINV.The severity of nausea and vomiting(remission rate of nausea and vomiting),adverse drug reactions and changes in quality of life after chemotherapy were compared between the two groups.Result:The nausea and vomiting remission rate of observation group was higher than that of control group(P<0.05).There was no significant difference in the incidence of adverse drug reactions between the two groups(P>0.05).The scores of the two subscales and total scores of the functional living index-emesis(FLIE)after chemotherapy in the observation group were higher than those in the control group,the differences were statistically significant(P<0.001).Conclusion:Prophylactic use of Netupitant and Palonosetron Hydrochloride Capsules antiemetic regimen can effectively improve the severity of CINV of Cisplatin regimen,improve the quality of life of patients,and do not increase the incidence of adverse reactions.
Netupitant and Palonosetron Hydrochloride CapsulesCisplatinChemotherapy-induced nausea and vomiting
万方数据
维普
